Evidence map›Paper›PMID 27738910›Full record

ReviewMolecular diagnosis & therapy2017

Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress.

Ashvini Keshavan, Amanda Heslegrave, Henrik Zetterberg, Jonathan M Schott

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diagnosis & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Ashvini KeshavanDementia Research Centre, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Box 16, Queen Square, London, WC1N 3BG, UK.
Amanda HeslegraveDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
Henrik ZetterbergDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
Jonathan M SchottDementia Research Centre, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Box 16, Queen Square, London, WC1N 3BG, UK. j.schott@ucl.ac.uk.
University College London · GBNational Hospital for Neurology and Neurosurgery · GBUniversity of Gothenburg · SE

Funding

Medical Research Council MR/L023784/1Medical Research Council MR/L023784/2
6 · The paper itself

Abstract

Biomarkers in Alzheimer's disease (AD) have the potential to allow early and more accurate diagnosis, predict disease progression, stratify individuals and track response to candidate therapies in drug trials. The first fluid biomarkers reflecting aspects of AD neuropathology were identified in cerebrospinal fluid (CSF) in the 1990s. Three CSF biomarkers (amyloid-β 1-42, total tau and phospho-tau) have consistently been shown to have diagnostic utility and are incorporated into the new diagnostic criteria for AD. These markers have also been shown in longitudinal studies to predict conversion of mild cognitive impairment to AD. However, a key issue with the use of CSF biomarkers as a screening test is the invasiveness of lumbar puncture. Over the last 20 years there has been an active quest for blood biomarkers, which could be easily acquired and tested repeatedly throughout the disease course. One approach to identifying such markers is to attempt to measure candidates that have already been identified in CSF. Until recently, this approach has been limited by assay sensitivity, but newer platforms now allow single molecule-level detection. Another approach is identification of candidates in large multiplex panels that allow for multiple analytes to be quantified in parallel. While both approaches show promise, to date no blood-based biomarker or combination of biomarkers has sufficient predictive value to have utility in clinical practice. In this review, an overview of promising blood protein candidates is provided, and the challenges of validating and converting these into practicable tests are discussed.

Indexed as

Alzheimer DiseaseBiomarkersDisease ProgressionHumansNeurofilament Proteinstau ProteinsBiomarkersNeurofilament Proteinstau Proteins

Identifiers

PMID27738910
OpenAlexW2530387364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.